• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Vasconcelles Michael

    6/18/25 7:41:26 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DAWN alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    VASCONCELLES MICHAEL

    (Last) (First) (Middle)
    C/O DAY ONE BIOPHARMACEUTICALS, INC.
    1800 SIERRA POINT PARKWAY, SUITE 200

    (Street)
    BRISBANE CA 94005

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/16/2025
    3. Issuer Name and Ticker or Trading Symbol
    Day One Biopharmaceuticals, Inc. [ DAWN ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Head of Research and Dev.
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Charles N. York II, as Attorney-in-Fact 06/18/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $DAWN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DAWN

    DatePrice TargetRatingAnalyst
    10/9/2024$32.00 → $33.00Buy
    Needham
    8/1/2024$11.00 → $24.00Underperform → Buy
    BofA Securities
    4/24/2024$30.00 → $33.00Buy
    Needham
    4/25/2023$34.00 → $9.00Buy → Underperform
    BofA Securities
    2/8/2023$40.00Overweight
    CapitalOne
    2/3/2023Perform
    Oppenheimer
    12/15/2022$35.00Buy
    H.C. Wainwright
    12/14/2022$40.00Buy
    Needham
    More analyst ratings

    $DAWN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

      Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive pipeline creation and execution BRISBANE, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Michael Vasconcelles, M.D., has joined the Company as Head of Research & Development (R&D). "We are thrilled to welcome Mike during this pivotal time at Day One. As an

      6/10/25 8:30:00 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Reports First Quarter 2025 Financial Results and Corporate Progress

      OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, May 6, 4:30 p.m. ET BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its first quarter 2025 financial results and highlighted recent corporate achievemen

      5/6/25 4:01:00 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

      BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the first quarter 2025. Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30 days

      4/22/25 8:30:00 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    SEC Filings

    See more
    • SEC Form 8-K filed by Day One Biopharmaceuticals Inc.

      8-K - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)

      6/3/25 4:01:19 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Day One Biopharmaceuticals Inc.

      144 - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

      5/16/25 4:09:31 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Day One Biopharmaceuticals Inc.

      144 - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

      5/16/25 4:08:57 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • April 30, 2024 - FDA Roundup: April 30, 2024

      For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

      4/30/24 3:20:20 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • April 26, 2024 - FDA Roundup: April 26, 2024

      For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

      4/26/24 3:10:22 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OJEMDA issued to DAY ONE BIOPHARMACEUTICALS INC

      Submission status for DAY ONE BIOPHARMACEUTICALS INC's drug OJEMDA (ORIG-1) with active ingredient TOVORAFENIB has changed to 'Approval' on 04/23/2024. Application Category: NDA, Application Number: 218033, Application Classification: Type 1 - New Molecular Entity

      4/24/24 12:52:43 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ai Day1 Llc bought $14,978,327 worth of shares (1,475,454 units at $10.15) (SEC Form 4)

      4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

      10/20/23 4:02:31 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham reiterated coverage on Day One Biopharmaceuticals with a new price target

      Needham reiterated coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $33.00 from $32.00 previously

      10/9/24 7:46:01 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Biopharmaceuticals upgraded by BofA Securities with a new price target

      BofA Securities upgraded Day One Biopharmaceuticals from Underperform to Buy and set a new price target of $24.00 from $11.00 previously

      8/1/24 6:23:36 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Day One Biopharmaceuticals with a new price target

      Needham reiterated coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $33.00 from $30.00 previously

      4/24/24 7:16:05 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Head of Research and Dev. Vasconcelles Michael

      4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

      6/18/25 7:42:38 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Vasconcelles Michael

      3 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

      6/18/25 7:41:26 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Grossman William

      4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

      6/4/25 5:54:17 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Leadership Updates

    Live Leadership Updates

    See more
    • Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

      Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive pipeline creation and execution BRISBANE, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Michael Vasconcelles, M.D., has joined the Company as Head of Research & Development (R&D). "We are thrilled to welcome Mike during this pivotal time at Day One. As an

      6/10/25 8:30:00 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

      Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D., Ph.D, co-founder and Head of Research & Development (R&D) of the Company, will be retiring effective at the end of 2024. He will continue to serve as a strategic advisor and consultant while the Company seeks a new Head of R&D. "Sam's passion for pediatric oncology

      11/20/24 4:30:00 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Announces Two New Appointments to Board of Directors

      BRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointments of Habib Dable and Dr. William Grossman to its Board of Directors. "We are excited to welcome Habib and Bill to our Board during this pivotal phase of our growth," said Jeremy Bender, Ph.D., chief executive officer of Day One. "Their deep expertise and leadership in oncology will further strengthen our Board and will be a great asset as we prepare for the potential launch of ou

      1/17/24 8:00:00 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Financials

    Live finance-specific insights

    See more
    • Day One Reports First Quarter 2025 Financial Results and Corporate Progress

      OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, May 6, 4:30 p.m. ET BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its first quarter 2025 financial results and highlighted recent corporate achievemen

      5/6/25 4:01:00 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

      BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the first quarter 2025. Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30 days

      4/22/25 8:30:00 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

       Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, February 25, 4:30 p.m. ET BRISBANE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its fourth quarter and full year 2024 financial results and highli

      2/25/25 4:05:00 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

      SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

      11/14/24 4:30:11 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

      SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

      11/7/24 9:24:55 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Day One Biopharmaceuticals Inc.

      SC 13G - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

      11/7/24 9:12:22 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care